1014 related articles for article (PubMed ID: 17979674)
21. The role of AGEs in cardiovascular disease.
Jandeleit-Dahm K; Cooper ME
Curr Pharm Des; 2008; 14(10):979-86. PubMed ID: 18473849
[TBL] [Abstract][Full Text] [Related]
22. Association between Advanced Glycation End Products, Soluble RAGE Receptor, and Endothelium Dysfunction, Evaluated by Circulating Endothelial Cells and Endothelial Progenitor Cells in Patients with Mild and Resistant Hypertension.
Gryszczyńska B; Budzyń M; Begier-Krasińska B; Osińska A; Boruczkowski M; Kaczmarek M; Bukowska A; Iskra M; Kasprzak MP
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412635
[TBL] [Abstract][Full Text] [Related]
23. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
Takeuchi M; Takino J; Yamagishi S
Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
[TBL] [Abstract][Full Text] [Related]
24. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
Yamagishi S; Taguchi K; Fukami K
Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
[TBL] [Abstract][Full Text] [Related]
25. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.
Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM
Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300
[TBL] [Abstract][Full Text] [Related]
26. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
Schmidt AM; Yan SD; Wautier JL; Stern D
Circ Res; 1999 Mar; 84(5):489-97. PubMed ID: 10082470
[TBL] [Abstract][Full Text] [Related]
27. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
[TBL] [Abstract][Full Text] [Related]
28. Advanced glycation end products, their receptors and diabetic angiopathy.
Wautier JL; Guillausseau PJ
Diabetes Metab; 2001 Nov; 27(5 Pt 1):535-42. PubMed ID: 11694852
[TBL] [Abstract][Full Text] [Related]
29. Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM.
Miranda ER; Fuller KNZ; Perkins RK; Beisswenger PJ; Farabi SS; Quinn L; Haus JM
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781793
[TBL] [Abstract][Full Text] [Related]
30. Activation of the receptor for advanced glycation end products system in women with severe preeclampsia.
Oliver EA; Buhimschi CS; Dulay AT; Baumbusch MA; Abdel-Razeq SS; Lee SY; Zhao G; Jing S; Pettker CM; Buhimschi IA
J Clin Endocrinol Metab; 2011 Mar; 96(3):689-98. PubMed ID: 21325454
[TBL] [Abstract][Full Text] [Related]
31. Unlocking the biology of RAGE in diabetic microvascular complications.
Manigrasso MB; Juranek J; Ramasamy R; Schmidt AM
Trends Endocrinol Metab; 2014 Jan; 25(1):15-22. PubMed ID: 24011512
[TBL] [Abstract][Full Text] [Related]
32. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
Takeuchi M; Yamagishi S
Curr Pharm Des; 2008; 14(10):973-8. PubMed ID: 18473848
[TBL] [Abstract][Full Text] [Related]
33. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.
Thomas MC; Woodward M; Neal B; Li Q; Pickering R; Marre M; Williams B; Perkovic V; Cooper ME; Zoungas S; Chalmers J; Hillis GS;
Diabetes Care; 2015 Oct; 38(10):1891-7. PubMed ID: 26253728
[TBL] [Abstract][Full Text] [Related]
34. Phytochemicals Against Advanced Glycation End Products (AGEs) and the Receptor System.
Yamagishi SI; Matsui T; Ishibashi Y; Isami F; Abe Y; Sakaguchi T; Higashimoto Y
Curr Pharm Des; 2017; 23(8):1135-1141. PubMed ID: 27774900
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular disease: what's all the AGE/RAGE about?
Barlovic DP; Thomas MC; Jandeleit-Dahm K
Cardiovasc Hematol Disord Drug Targets; 2010 Mar; 10(1):7-15. PubMed ID: 20041839
[TBL] [Abstract][Full Text] [Related]
36. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
[TBL] [Abstract][Full Text] [Related]
37. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.
Geroldi D; Falcone C; Emanuele E
Curr Med Chem; 2006; 13(17):1971-8. PubMed ID: 16842191
[TBL] [Abstract][Full Text] [Related]
38. Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.
Pertynska-Marczewska M; Merhi Z
Reprod Sci; 2015 Jul; 22(7):774-82. PubMed ID: 25228634
[TBL] [Abstract][Full Text] [Related]
39. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
[TBL] [Abstract][Full Text] [Related]
40. [Therapeutic intervention in diseases with advanced glycation end products in their pathogenesis].
Zuwała-Jagiełło J
Pol Merkur Lekarski; 2009 Aug; 27(158):152-6. PubMed ID: 19856885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
